Press Releases
Search
-
22 Apr 2025
Business & Solutions
WATCHFIRE™ by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of its WATCHFIRE™ molecular testing solution. The WATCHFIRE™ Respiratory (R) Panel, targeting 22 pathogens*, will run on the BIOFIRE® FILMARRAY® TORCH instrument, integrated with FIREWORKS™ software, to deliver real-time trending of viruses and bacteria present in wastewater samples.
-
17 Apr 2025
Financial Information
First-Quarter 2025 Business Review
Consolidated sales totaled €1,098 million in the first quarter of 2025, up 13.7% as reported from €965 million in first quarter of 2024. Organic growth (at constant exchange rates and scope of consolidation) stood at +12.7%, above expectations.
-
07 Apr 2025
Antimicrobial Resistance
bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of LUMED™ APSS™, an advanced clinical decision support system (CDSS) designed to enhance antimicrobial stewardship programs (ASP) and improve patient outcomes.
-
18 Mar 2025
Antimicrobial Resistance
bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat antimicrobial resistance, and industrial laboratories to identify contaminants for ensuring consumer safety.
-
07 Mar 2025
Financial Information
bioMérieux – 2024 Financial Results
Consolidated sales amounted to €3,980 million in 2024, up 10.3% like-for-like from €3,675 million in the prior year period. Reported growth stood at +8.3% for the period.
-
13 Feb 2025
Business & Solutions
bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of Listeria monocytogenes
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry.